Improving the role of immune checkpoint inhibitors in the management of advanced urothelial carcinoma, where do we stand?

被引：2
|
作者：
Houssiau, Helene [1 ]
Seront, Emmanuel [1 ]
机构：
[1] Ctr Hosp Jolimont, Dept Med Oncol, Rue Ferrer 159, B-7100 Haine Saint Paul, Belgium
来源：
TRANSLATIONAL ONCOLOGY | 2022年 / 19卷
关键词：
Urothelial carcinoma; Immune checkpoint inhibitors; Maintenance strategy; PD-L1; Platinum-based strategy; CISPLATIN-INELIGIBLE PATIENTS; INVASIVE BLADDER-CANCER; PHASE-II TRIAL; SINGLE-ARM; SUPPORTIVE CARE; OPEN-LABEL; CHEMOTHERAPY; MULTICENTER; ATEZOLIZUMAB; PLUS;
D O I：
10.1016/j.tranon.2022.101387
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Immune checkpoint inhibitors (ICIs) have significantly improved the outcome of patients with metastatic umthelial cancer (mUC). If these agents were first used in monotherapy after failure of platinum-based chemotherapy, new strategies have been evaluated in the last years, including association of ICIs, ICI plus chemotherapy association or maintenance therapy. This maintenance concept allows a better management of mUC, which is particularly interesting in cisplatin-ineligible patients. This paper aims to review the current knowledge of ICIs in urothelial carcinoma as well as the new indications of these agents in mUC.
引用
收藏
页数：11
相关论文
共 50 条
  • [21] Where do immune checkpoint inhibitors stand in the management of thymic epithelial tumors?
    Saleh, Khalil
    Khalifeh-Saleh, Nadine
    Kourie, Hampig Raphael
    IMMUNOTHERAPY, 2018, 10 (10) : 823 - 826
  • [22] First-line checkpoint inhibitors in PD-L1-positive patients with advanced urothelial carcinoma
    Tsimafeyeu, Ilya
    Tjulandin, Sergei
    BJU INTERNATIONAL, 2019, 123 (04) : 563 - 565
  • [23] Urothelial carcinoma: the development of FGFR inhibitors in combination with immune checkpoint inhibitors
    Qin, Qian
    Patel, Vaibhav
    Galsky, Matthew D.
    EXPERT REVIEW OF ANTICANCER THERAPY, 2020, 20 (06) : 503 - 512
  • [24] The Use of Immune Checkpoint Inhibitors in Oncology and the Occurrence of AKI: Where Do We Stand?
    Franzin, Rossana
    Netti, Giuseppe Stefano
    Spadaccino, Federica
    Porta, Camillo
    Gesualdo, Loreto
    Stallone, Giovanni
    Castellano, Giuseppe
    Ranieri, Elena
    FRONTIERS IN IMMUNOLOGY, 2020, 11
  • [25] Prevalence of immune-related adverse events and anti-tumor efficacy in advanced/metastatic urothelial carcinoma following immune-checkpoint inhibitor treatment
    Morales-Barrera, Rafael
    Villacampa, Guillermo
    Vidal, Natalia
    Figols, Mariona
    Giner, Julia
    Bonfill, Teresa
    Suarez, Cristina
    Diaz, Nely
    Mateo, Joaquin
    Gonzalez, Macarena
    Domenech, Montserrat
    Puente, Javier
    Carles, Joan
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2023, 25 (12) : 3556 - 3564
  • [26] Immune checkpoint inhibitors in the treatment of oesophageal squamous cell carcinoma: where are we and where are we going?
    Chen, Ning
    Xu, Xiaoling
    Fan, Yun
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2023, 15
  • [27] Significance of PD-L1 in Metastatic Urothelial Carcinoma Treated With Immune Checkpoint Inhibitors
    Maiorano, Brigida Anna
    Di Maio, Massimo
    Cerbone, Linda
    Maiello, Evaristo
    Procopio, Giuseppe
    Roviello, Giandomenico
    JAMA NETWORK OPEN, 2024, 7 (03) : E241215
  • [28] Biomarkers of the Response to Immune Checkpoint Inhibitors in Metastatic Urothelial Carcinoma
    Chen, Siteng
    Zhang, Ning
    Wang, Tao
    Zhang, Encheng
    Wang, Xiang
    Zheng, Junhua
    FRONTIERS IN IMMUNOLOGY, 2020, 11
  • [29] Targeted Therapy for Advanced Urothelial Cancer of the Bladder: Where Do We Stand?
    Zhu, Zhaowei
    Shen, Zhoujun
    Xu, Chen
    ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY, 2012, 12 (09) : 1081 - 1087
  • [30] Current Landscape of Immune Checkpoint Inhibitors for Metastatic Urothelial Carcinoma: Is There a Role for Additional T-Cell Blockade?
    Ogbuji, Vanessa
    Paster, Irasema C.
    Recio-Boiles, Alejandro
    Carew, Jennifer S.
    Nawrocki, Steffan T.
    Chipollini, Juan
    CANCERS, 2024, 16 (01)
12345